Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/27/2011Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. difficile GDH Test
CINCINNATI--(BUSINESS WIRE)--Dec. 27, 2011-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard® C. difficile GDH. This test detects the C. difficile common antigen glutamate dehydrogenase (or GDH). This assay has already been successfully launched and accepted in global markets as an excellent screening option for C. difficile. The GDH commo... 
 Printer Friendly Version
12/12/2011Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus
CINCINNATI--(BUSINESS WIRE)--Dec. 12, 2011-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Group B Streptococcus (GBS) on the illumigene® platform. This innovative test is a strong addition to the illumigene platform. Group B Streptococcus, or GBS, continues to be a major perinatal pathogen, for both mothers and their infants, and is associa... 
 Printer Friendly Version
11/10/2011Meridian Bioscience Reports Fourth Quarter and Full-Year 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI, Nov 10, 2011 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fourth quarter and record full-year fiscal 2011 net sales of $41.3 million and $159.7 million, respectively, increases of 16% and 12%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2011 operating income of $9.9 million and $40.0 million, respective... 
Download PDFPrinter Friendly Version
8/25/2011Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance
CINCINNATI, Aug 25, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2012 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2012, management expects net sales to be in the range of $183 to $192 million and per share diluted earnings to be between $0.85 and $0.89. The per ... 
 Printer Friendly Version
8/23/2011Meridian Bioscience Establishes Direct Sales in Australia Through Bioline Australia
CINCINNATI, Aug 23, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., (NASDAQ: VIVO) is pleased to announce the commencement of a new, direct distribution arrangement in Australia for the Meridian diagnostic products. Meridian is transitioning the sales of the Meridian diagnostic products from its current distributor to its direct sales force through Bioline (Aust) Pty Ltd. (Bioline Australia), a wholly-owned subsidiary of Meridian Bioscience, Inc. Bi... 
 Printer Friendly Version
8/9/2011Meridian Bioscience Launches ImmunoCard(R)C. difficile GDH Assay in Europe
CINCINNATI, Aug 09, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ:VIVO) is pleased to announce the launch of a new Clostridium difficile rapid test, ImmunoCardC. difficile GDH. This assay detects the common antigen, Glutamate dehydrogenase, produced by toxigenic and non-toxigenic strains of Clostridium difficile. Toxigenic strains of Clostridium difficile are frequently associated with hospital and community acquired diarrhea and can lead to lif... 
 Printer Friendly Version
7/21/2011Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2011 Guidance
CINCINNATI, Jul 21, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2011 third quarter and nine months net sales of $40.1 million and $118.4 million, respectively, increases of 18% and 10%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $10.1 million, a... 
 Printer Friendly Version
6/10/2011Meridian Tests Detect Deadly Toxins Produced by E. coli O104 Outbreak Strain
CINCINNATI, Jun 10, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its tests detect the deadly toxins produced by the recent outbreak strain E. coli O104:H4. E. coli O104:H4 is the novel shiga toxin-producing strain associated with a number of deaths in Europe. It has also caused hemolytic uremic syndrome (HUS) (a type of kidney failure) in hundreds of others. In the United States, one confirmed and three suspec... 
 Printer Friendly Version
6/7/2011E. coli O104 Outbreak Highlights Need for Rapid, Accurate Testing Options
CINCINNATI, Jun 07, 2011 (BUSINESS WIRE) --The recent E. coli outbreak making headlines in Europe and the United States has been identified as a rare and unique strain, E. coli O104:H4. The outbreak strain is a Shiga toxin 2 type producing E. coli, and is of concern because initial lab findings have revealed various characteristics that make it more virulent and toxin producing. The most recent statistics show that 1,674 people have been infected with... 
 Printer Friendly Version
5/10/2011Meridian Bioscience Receives FDA Clearance for New Premier (TM) C. difficile GDH Assay
CINCINNATI, May 10, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new Clostridium difficile immunoassay named Premier(TM) C. difficile GDH. This product expands the Company's existing portfolio of C. difficile tests and has been available in Europe and the rest of world since October of 2010. The assay detects a c... 
 Printer Friendly Version
4/21/2011Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Apr 21, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year; reported second quarter operating income of $11.0 million, an... 
 Printer Friendly Version
3/2/2011Meridian Bioscience Receives FDA Clearance For New illumigene(R)C. difficile Pediatric Claim
CINCINNATI, Mar 02, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new pediatric claim for its illumigeneC. difficile (Clostridium difficile) molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflam... 
 Printer Friendly Version
1/20/2011Meridian Bioscience Reports First Quarter 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Jan 20, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported first quarter net sales of $37.3 million, a decrease of 12%, from the same period of the prior fiscal year; reported first quarter operating income of $9.1 million, a decrease of 34%, from the same period of the prior fiscal year; ... 
 Printer Friendly Version